Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Capitol Capsule: 10 years in, are SOX Act costs hampering biotech IPOs?

This article was originally published in Scrip

Executive Summary

Even with new exemptions for emerging-growth companies provided in the new JOBS Act, the costs of complying with auditing regulations put in place in 2002 under Section 404(b) of the Sarbanes-Oxley (SOX) Act are keeping many biotechs from going public, Jeffrey Hatfield, CEO of privately held Vitae Pharmaceuticals, told lawmakers last week.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts